Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - Deferred ChargesAmortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Celularity (CELU) EBITDA (2020 - 2025)

Celularity (CELU) has disclosed EBITDA for 6 consecutive years, with -$24.4 million as the latest value for Q4 2025.

  • For Q4 2025, EBITDA fell 83.23% year-over-year to -$24.4 million; the TTM value through Dec 2025 reached -$91.7 million, down 58.4%, while the annual FY2025 figure was -$91.7 million, 58.4% down from the prior year.
  • EBITDA hit -$24.4 million in Q4 2025 for Celularity, down from -$23.1 million in the prior quarter.
  • Across five years, EBITDA topped out at $49.9 million in Q3 2021 and bottomed at -$93.9 million in Q3 2023.
  • Average EBITDA over 5 years is -$19.5 million, with a median of -$20.9 million recorded in 2024.
  • On a YoY basis, EBITDA climbed as much as 1139.08% in 2021 and fell as far as 29007.3% in 2021.
  • Celularity's EBITDA stood at -$4.0 million in 2021, then skyrocketed by 699.18% to $24.2 million in 2022, then tumbled by 70.45% to $7.2 million in 2023, then crashed by 285.91% to -$13.3 million in 2024, then crashed by 83.23% to -$24.4 million in 2025.
  • According to Business Quant data, EBITDA over the past three periods came in at -$24.4 million, -$23.1 million, and -$24.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.